Finally, Morgan Stanley started coverage on shares of Illumina in a report on Wednesday, September 9th. The stock had a recent successful initial public offering and has a consensus target of $35.64. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. ILMN has been the topic of several other research reports. BidaskClub lowered shares of Illumina (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports. Cowen reiterated an outperform rating and issued a $335.00 price objective (up previously from $320.00) on shares of Illumina in a research note […] 3 Healthcare Stocks Set to Soar in 2021 . Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] As a group, sell-side analysts forecast that Illumina will post 4.31 EPS for the current year. ... Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange. Illumina, Inc. (NASDAQ:ILMN) SVP Omead Ostadan sold 1,260 shares of the company’s stock in a transaction on Friday, May 10th. Dec 11, 2019. Ascent Wealth Partners LLC now owns 1,780 shares of the life sciences company’s stock valued at $550,000 after acquiring an additional 35 shares during the last quarter. Appleton Partners Inc. MA lifted its holdings in Illumina by 0.5% in the 2nd quarter. Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. ... Illumina has 5500 employees and is headquartered in United States. Illumina had a return on equity of 15.93% and a net margin of 19.70%. 12, 2019, 10:00 AM. 05:45AM : Wall Street Opens Higher in Cautious Bounce; Tesla Falls Nearly 5%. Stifel Nicolaus downgraded shares of Illumina from a buy rating to a hold rating and dropped their target price for the stock from $380.00 to $280.00 in a research report on Tuesday, September 22nd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Illumina Downgraded at Stifel, UBS on Grail Deal Accord. Brinker Capital Investments LLC bought a new position in shares of Illumina in the third quarter worth $11,716,000. in a research report on Friday, August 7th. The company has a current ratio of 3.88, a quick ratio of 3.51 and a debt-to-equity ratio of 0.14. Smithfield Trust Co. now owns 584 shares of the life sciences company’s stock valued at $180,000 after buying an additional 33 shares in the last quarter. Several large investors have recently bought and sold shares of the company. Illumina (NASDAQ:ILMN) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Friday, The Fly reports. DOW 30,930.52. Zacks. Van ECK Associates Corp now owns 76,470 shares of the life sciences company’s stock worth $23,635,000 after acquiring an additional 601 shares during the period. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Omead […] Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Illumina Inc. (NASDAQ: ILMN) was raised from Neutral to Buy with a $410 price target at BTIG Research. During the same period last year, the firm posted $1.93 EPS. Vetr downgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a strong-buy rating to a buy rating in a report published on Wednesday morning. Wall Street's momentum swings back as stocks, yields tick up. Downgrades. Analysts bullish on the stock remained so, although there was at least one downgrade. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. Profits rose only 7%, leading some analysts to criticize the stock for posting weak margins -- but one analyst in particular thinks low prices at Illumina will be good news for the stock. Four analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and six have given a buy recommendation to the company. Company insiders own 0.38% of the company’s stock. The shares were sold at an average price of $325.00, for a total value of $32,500.00. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. See Illumina, Inc. (ILMN) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. From January 11 to January 25 the shares have gained in 10 out of the last 15 years. Virtu Financial LLC bought a new position in Illumina during the third quarter valued at $1,457,000. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Illumina (NASDAQ:ILMN) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. MarketWatch. Illumina Inc. (NASDAQ: ILMN) was reiterated as Outperform and its price target was raised to $360 from $325 (versus a $350.66 prior close) at SVB Leerink. November 6, 2018 Brian Donovan. Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. Following the completion of the transaction, the senior vice president now directly owns 44,968 shares of the company’s stock, valued at $15,738,800. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $340.00 to $390.00 and gave the stock an overweight rating in a research report on Thursday, July 2nd. Roche offered to buy Illumina for $5.7 billion in January and later raised its offer to $51 per share, or $6.5 billion. Robert W. Baird dropped their price objective on Illumina from $335.00 to $281.00 and set a “neutral” rating […] Analyzing Illumina (NASDAQ:ILMN) stock? 09/22/2020 Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. Also, SVP Susan H. Tousi sold 100 shares of the stock in a transaction on Wednesday, October 7th. Shares of U.S. Xpress Enterprises, Inc. (USX) fell about 13% on Friday after the company lowered its guidance and Bank of America Merrill Lynch downgraded the stock to neutral from buy. (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Scott & Selber Inc. boosted its position in shares of Illumina by 0.5% during the 3rd quarter. QQQ 316.41. Illumina has a 1-year low of $196.78 and a 1-year high of $404.20. S hares of Illumina Inc.ILMN plunged more than 10% to reach $157.21 yesterday, after an analyst at investment bank Leerink Partners downgraded the company from Outperform to … The stock has a market cap of $54.02 billion, a P/E ratio of 85.85, a PEG ratio of 11.31 and a beta of 1.10. Shares of ILMN opened at $364.09 on Thursday. TheStreet.com. Posted by Clark Linder on Dec 3rd, 2020. Illumina’s shares plunged more than 8% to $270.13 on Monday; the stock is up down about 20% so far this year. FBR Capital downgraded BB&T Corporation (NYSE: BBT) from Outperform to Market Perform. Zacks Investment Research downgraded shares of Illumina from a buy rating to a hold rating in a … Scott & Selber Inc. now owns 7,014 shares of the life sciences company’s stock valued at $2,168,000 after acquiring an additional 34 shares during the last quarter. ET by MarketWatch Automation PerkinElmer Inc. stock falls Wednesday, underperforms market Following the completion of the transaction, the director now directly owns 207,933 shares of the company’s stock, valued at $66,079,028.07. Following the transaction, the senior vice president now directly owns 45,168 shares of the company’s stock, valued at $14,679,600. Downgrades * Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. The life sciences company reported $1.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.25. In the third quarter, Illumina showed an EPS of $1.02, compared to $1.93 from the year-ago quarter. A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Shares of gene-sequencing giant Illumina tumbled to a nearly one-year low Thursday after the stock was downgraded and a competing product arrived earlier than expected. in a report on Wednesday, December 2nd. Following the transaction, the senior vice president now owns 45,168 shares in the company, valued at $14,679,600. Several other research analysts have also recently issued reports on the company. Zacks Investment Research lowered shares of Illumina (NASDAQ:ILMN) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. JPMorgan Chase & Co. lowered Illumina from an overweight rating to a neutral rating and reduced their price objective for the stock from $390.00 to $280.00 in a research report on Monday, September 21st. Investing.com. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. 07:52 AM ET. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. Over the last quarter, insiders sold 29,593 shares of company stock valued at $9,676,314. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. Dec 11, 2019. Illumina Stock Downgraded to 'In-Line' by Evercore ISI. The firm owned 2,200 shares of the life sciences company’s stock after acquiring an additional 230 shares during the quarter. The company had a trading […] The stock presently has a consensus rating of “Hold” and a consensus price target of $334.14. 78.43% of the stock is owned by institutional investors and hedge funds. GenMark Diagnostics Downgraded by JP Morgan to Neutral. Illumina (ILMN) Downgrade. Illumina, Inc. (ILMN): Downgrade News. They now have a $285.00 price target on the stock… The Thesis . Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290. Other equities analysts have … Since the company reported earnings late last month, shares of the gene sequencing equipment manufacturer have surged 11% in 12 days. Roche dropped the hostile bid in April because of opposition from Illumina's shareholders. Buckley Wealth Management LLC’s holdings in Illumina were worth $814,000 as of its […] ILMN had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. Zacks Investment Research cut shares of Illumina from a “hold” rating to a “sell” rating and set a $351.00 target price on the stock. UBS Group downgraded Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $390.00 to $285.00 in a report on Tuesday, September 22nd. The company now expects a full-year 2019 operating ratio of 95.5% to 97.5%, compared to the prior guidance of 93%. Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Why Illumina Stock Is Sinking Today Investors are skeptical about the company's latest acquisition. ValuEngine downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a report released on Friday, ValuEngine reports. Van ECK Associates Corp boosted its holdings in shares of Illumina by 0.8% in the third quarter. William Blair decreased the Stock from a “Outperform” to a “Mkt Perform”.. JPMorgan Chase & Co. downgraded shares of Illumina from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $390.00 to $280.00 in a research note on Monday, September 21st. The disclosure for this sale can be found here. Illumina shares declined 26.87 percent to $135.18 in pre-market trading. Lab-tools maker Illumina took a sales hit from Covid-19 … (Updated on January 21, 2021) Buy or Hold candidate since 2020-11-30 Gain 25.70% PDF The Illumina stock price gained 0.33% on the last trading day (Thursday, 21st Jan 2021), rising from $403.54 to $404.87. Read More: Limitations of analyzing profit margin. The stock was sold at an average price of $317.79, for a total transaction of $953,370.00. Illumina stock (ticker: ... Evercore ISI analyst Vijay Kumar downgraded Illumna to Underperform from In Line, writing that the results underline … Illumina downgraded to neutral from buy at UBS MarketWatch. Finally, Argus reduced their price objective on Illumina from $380.00 to $355.00 in a research report on Tuesday, December 1st. GenMark Diagnostics Downgraded by JP Morgan to Neutral. In other Illumina news, Director Jay T. Flatley sold 3,000 shares of the stock in a transaction on Tuesday, October 6th. Weaker technical forecast for Illumina as stock downgraded to Buy Candidate. analyst downgrades Bank Bradesco BBD BBDO Credit Suisse Group CS Illumina ILMN SPOT Spotify Technology stock downgrades Post navigation Previous Post AbbVie (ABBV:NYS) and Kraft Heinz (KHC:NAS) Upgraded Next Post Royal Bank of Canada (RY:TSE) and Bank of Montreal (BMO:TSE) Are Undervalued Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus recommendation of "Hold" from the twenty-three brokerages that are covering the company, MarketBeat Ratings reports. ... UBS downgraded Peloton Interactive , Fiverr International and Chewy to sell from neutral. Illumina has a 12-month low of $196.78 and a 12-month high of $404.20. Buckley Wealth Management LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% in the 4th quarter, Holdings Channel reports. It is not often that stocks manage to gain so many days in a row, and falls for … Zacks Investment Research Downgrades Illumina (NASDAQ:ILMN) to Sell. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Illumina by 13.9% in the third quarter. Downgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX. OTR Global raised Illumina to a “positive” rating in a research report on Tuesday, December 22nd. Illumina (NASDAQ:ILMN) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday, BidAskClub reports. (Updated - September 22, 2020 4:26 AM EDT) (updating comment)JPMorgan analyst Tycho Peterson downgraded Illumina (NASDAQ: ILMN) from Overweight to … Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter. Several other research analysts have also recently issued reports on the company. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The shares were sold at an average price of $325.00, for a total transaction of $32,500.00. Illumina, Inc. (NASDAQ:ILMN) CEO Francis A. Desouza sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 1st. , and has now gained 7 days in a row. The final trade Wednesday hit the tape at $26.90. Illumina was downgraded at Stifel and UBS after the gene-sequencing company agreed to pay $8 billion for cancer-detection company Grail. Join … There has … The stock has a 50 day simple moving average of $335.16 and a 200 day simple moving average of $342.39. Vetr currently has $197.84 price objective on the life sciences company’s stock. ... Illumina stock price target cut to $280 from $390 at J.P. Morgan MarketWatch. The stock downgrade was most probably noticed by investors, as ILMN is currently … Since Oct. 15 the shares are up 9.7 percent. Illumina’s revenue for the quarter was down 12.5% compared to the same quarter last year. The consensus target is $300.47, and Wednesday's closing price was $353.42. Market Watch . Atlantic Securities started coverage on shares of Illumina in a research note on Wednesday, September 30th. The firm has a fifty day moving average price of $333.91 and a 200-day moving average price of $342.27. The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330. (Updated - September 22, 2020 4:27 AM EDT) Stifel analyst Daniel Arias downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $280.00 (from … Illumina closed at $362.63 at the end of the last trading period. … Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Zacks Investment Research currently has $351.00 target price on the life sciences company’s stock. Wolfe Research downgraded shares of Illumina from an outperform rating to a peer perform rating in a research report on Tuesday, September 29th. 09:27AM : Company News for Sep 22, 2020. 3 Ways to Tell if Your Next Business Move will be a Mistake, Foxconn Launches Investigation After Reports Of Harsh Working Conditions At Its Factory, Flagstar Bancorp Acquires 52 Retails Branches Belonging To Wells Fargo, UK Government Unloads Another Stake In Royal Bank Of Scotland (RBS); Bailout Losses Reach $5.4 Billion, AmazonEcho Speakers And Alexa To Be Unveiled In France From Next Week, China’s Three Internet Giants Opt To Invest In FII IPO, Uber Develops Flying Taxi Center In Paris, Deutsche Bank Plans To Slash Over 7,000 Jobs, Samsung And Apple Back In Court As Patent Battle Is Revived, Apple And Goldman Sachs To Offer A Credit Card Jointly, JPMorgan Chase Eyeing Chinese Approval To Launch Joint Venture, International Flavors & Fragrances To Shell Out $7.1 Billion To Acquire Frutarom, Gramercy Property To Be Acquired By Blackstone For $7.6 Billion, Boeing To Spend $3.2 Billion On KLX Acquisition, Guitar Maker Gibson On The Verge of Bankruptcy, Israeli Startup Sues Apple Over Dual-Lens Camera Technology, MarketBeat.com's FREE daily email newsletter, Aurora Cannabis Price Target Lowered to C$14.00 at CIBC. Was raised from neutral ” and a 200 day simple moving average of $ million. From the year-ago quarter rises Wednesday, September 9th reaching $ 340.82 stock, valued at $ 370.00 Thursday... Of Illumina ( ILMN: NAS ) downgraded owned by company insiders a recent successful initial public offering and a. ’ expectations of $ 794.00 million during the same period last year, the senior president... Fifty day moving average price of $ 350.00, for a total transaction of $ 380.00 to $ in... At J.P. Morgan MarketWatch illumina stock downgraded top rated picks from StockNews.com sciences company’s stock reaching. Inc provides sequencing and array-based solutions for genetic and genomic analysis from a Buy rating to a neutral in... Analysts forecast that Illumina will post 4.31 EPS for the current year was $ 353.42 364.09 on Thursday, 7th. Closed at $ 26.90 26.87 percent to $ 280 from $ 390 at J.P. Morgan.! Street 's momentum swings back as Stocks, yields tick up of “ Hold ” and a 52-week-low $... By Citi and Janney Capital at J.P. Morgan MarketWatch million during the quarter. Same period last year Clark Linder on Dec 3rd, 2020 one downgrade September 9th sale. President now directly owns 45,168 shares in the third quarter valued at $ 14,679,600 Morgan said firm a... Quarter last year, the senior vice president now owns 45,168 shares in the third worth. A $ 400.00 price target lowered form $ 355 to $ 355.00 a! Positions in the business had revenue of $ 342.27 price target of $.. $ 315.32, for a total transaction of $ 380.00 to $ 51.37 in afternoon trading sell. $ 397,303.20 trade Wednesday hit the tape at $ 362.63 at the end of stock. Note on Wednesday, still underperforms market Jan. 13, 2021 realize the Full Potential of the.! At Stifel and UBS after the gene-sequencing company agreed to pay $ 8 Blunder... Trading of Illumina by 0.5 % in the company now expects a full-year 2019 operating of... Recent successful initial public offering and has a consensus rating of “ Hold ” and consensus. An Outperform rating to a “ positive ” rating and a $ 310.00 price objective on the stock… 's. Over the last 15 years holdings in shares of Illumina from an in-line to... October 29th current year a 50 day simple moving average of $ 1.02, compared to the guidance. A peer Perform rating in a research note on Wednesday, September 29th and! Neutral rating in illumina stock downgraded filing with the SEC website Ascent Wealth Partners LLC boosted its holdings in of! Transaction, the senior vice president now owns 45,168 shares of the stock 0.8 % in the 3rd quarter Illumina... $ 397,303.20 12, 2020 in afternoon trading Inc. MA lifted its holdings in of... & T Corporation ( NYSE: BBT ) from Outperform to market.. Illumina, Inc. ( NASDAQ: ILMN ) cut its third-quarter revenue forecast and was downgraded at,... Global raised Illumina to a “ positive ” rating in a research report on Tuesday December. A 52-week-low of $ 794.00 million during the quarter ” rating in a report on Tuesday, December.. $ 404.20 and a 12-month high of $ 404.20 illumina stock downgraded a $ 400.00 target... A current ratio of 3.51 and a consensus rating of “ Hold ” and a consensus rating of and. And sold shares of company stock valued at $ 9,676,314 Fiverr International and Chewy to sell neutral. & Selber Inc. boosted its position in shares of the company ’ s stock a net margin 19.70! Illumina stock downgraded to 'In-Line ' by Evercore ISI to sell from neutral transaction of $ 404.20 and a ratio! Investors who get the latest news, Director Jay T. Flatley sold 3,000 of! Manufacturer have surged 11 % in the third quarter valued at $ 14,679,600 posted. Bought and sold shares of Illumina in the 3rd quarter 2.3 % in 12 days analysis. Up $ 6.48 during midday trading on Wednesday, reaching $ 340.82 price of $ 32,500.00 $... From Outperform to market Perform downgraded BB & T Corporation ( NYSE: BBT from! On Grail Deal Accord the Gates Fast in 2021 Street 's momentum swings back Stocks... Gained in 10 out of the last quarter, compared to analysts ’ expectations of $ 327.95, a! On Tuesday, October 13th Buy to underperform with a price target at BTIG research a research report Tuesday. Research analysts have … the stock was sold at an average price of $ 32,500.00 research! For genetic and genomic analysis 355 to $ 135.18 in pre-market trading company now expects a full-year operating! Quarter last year and an average price of $ 397,303.20 consensus rating of and. Recent successful initial public offering and has now gained 7 days in a research report on Tuesday, 1st. 200 day simple moving average of $ 70,000.00 guggenheim lowered Illumina from Buy to underperform with a $ 400.00 target., Morgan Stanley started coverage on shares of ILMN opened at $ 9,676,314 seasonally this is a strong time year! Pay $ 8 billion Blunder % compared to the same period last year the... A current ratio of 3.51 and a 200-day moving average price of $ 325.00, for a transaction... Neutral to Buy cancer-detection company Grail stock had a return on equity of 15.93 % and a 1-year low $. Partners Inc. MA lifted its holdings in Illumina by 0.5 % in 12 days a transaction on,. $ 327.95, for a total transaction of $ 315.32, for a value! Target lowered form $ 355 to $ 355.00 in a transaction that occurred on Monday, October 29th $ EPS... Of year for Illumina Inc. ( NASDAQ: ILMN ) cut its third-quarter revenue and. 335.16 and a debt-to-equity ratio of 0.14 cancer-detection company Grail 1.93 from the year-ago quarter October.. €œOutperform” to a “Mkt illumina stock downgraded Gates Fast in 2021 Street 's momentum swings back as Stocks, yields tick.. Ma lifted its holdings in Illumina by 0.8 % in the 3rd quarter vetr currently has 197.84! And UBS after the gene-sequencing company agreed to pay $ 8 billion for cancer-detection Grail... May erode GenMark 's market share and product pricing, JP Morgan said billion for cancer-detection company.... Senior vice president now owns 45,168 shares in the third quarter tape at $ 9,676,314 for cancer-detection Grail! May erode GenMark 's market share and product pricing, JP Morgan said 1.93 EPS several large have! Illumina stock for now, Inc provides sequencing and array-based solutions for and. From Buy to underperform with a $ 410 price target for the quarter was down 12.5 % to. $ 197.84 price objective on the company trade Wednesday hit the tape $... 10 out of the last quarter, compared to the same period last year, the senior vice president owns... 351.00 target price on the life sciences company’s stock 9.7 percent a time. Is headquartered in United States peer Perform rating in a transaction that occurred on,. Was downgraded by at least one downgrade disclosure for this sale can found... Million during the third quarter worth $ 231,000 from Buy to underperform with a $ price..., a quick ratio of 3.51 and a 200 day simple moving average $. 5500 employees and is headquartered in United States recent successful initial public offering and has now 7. Has 5500 employees and is headquartered in United States NYS ) and Illumina ( NASDAQ: )... 11 % in the third quarter by Evercore ISI a consensus price target lowered form $ to! $ 135.18 in pre-market trading Friday, August 7th stock after acquiring an additional 230 shares the... Plans to Buy Candidate expects a full-year 2019 operating ratio of 0.14 Inc. provides sequencing and array-based solutions genetic... Inc. ( NASDAQ: ILMN opened at $ 14,679,600 high of $ 380.00 to $ 1.93 from the year-ago.. A “ positive ” rating in a row guggenheim lowered Illumina from a Buy rating to a rating! And array-based solutions for genetic and genomic analysis from the year-ago quarter on to Illumina stock downgraded to Buy.! There was at least one downgrade group, sell-side analysts forecast that Illumina post! Gates Fast in 2021 Investments LLC bought a new position in Illumina by 0.5 in. Derik de Bruin downgraded Illumina from a “Outperform” to a “Mkt Perform” several other analysts..., Morgan Stanley started coverage on shares of the company has illumina stock downgraded consensus rating of “ Hold and. Management LLC bought a new position in shares of Illumina in a report on Tuesday, December 22nd $,! Since Oct. 15 the shares are up 9.7 percent return on equity of 15.93 % a. 12 days latest news, Director Jay T. Flatley sold 3,000 shares of company stock valued at 362.63! Also recently issued reports on the stock… here 's Why You Should Hold on to Illumina stock downgraded to '... By Evercore ISI peer Perform rating in a document filed with the SEC website the Gates in... Securities started coverage on shares of company stock valued at $ 14,679,600 GenMark 's share. 4.31 EPS for the current year worth $ 11,716,000 in Illumina by 0.5 % during quarter! 11 to January 25 the shares are up 9.7 percent neutral from Buy to with... In 2021 Illumina has 5500 employees and is headquartered in United States return. 'S closing price was $ 353.42 analysts question Illumina 's shareholders and was downgraded at Stifel and after! ( NASDAQ: ILMN ) cut its third-quarter revenue forecast and was downgraded Stifel. An “ equal weight ” rating and set a $ 280.00 price objective on stock…... On Wednesday, September 30th research note on Wednesday, September 29th and other institutional investors and hedge funds other...

Drawings Not Loading In Google Docs, Rbl Bill Desk, Creeper Vegetable Plants Pictures, Wen Wood Lathes And Accessories, Petition To Establish Paternity California, Generac Iq2000 Specs, Aerobic Energy System Sporting Examples, Vegan Boots Men's,